Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 20/20 | 0.77 |
| ▸ | KCNQ2 | O43526 | 20/20 | 0.77 |
| ▸ | KCNE1 | P15382 | 15/20 | 0.67 |
| ▸ | KCNQ1 | P51787 | 15/20 | 0.67 |
| ▸ | BACE1 | P56817 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL774620 | 0.88 | KCNQ3 (0.59) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL774990 | 0.88 | KCNQ3 (0.59) | KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL775201 | 0.87 | KCNQ3 (0.58) | KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL14339874 | 0.87 | KCNQ3 (1.00) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL776898 | 0.85 | KCNQ3 (0.56) | KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL777653 | 0.85 | MEN1 (0.64) | KCNQ3KCNQ2 | |
| SCHEMBL3203522 | 0.83 | NAMPT (0.72) | — | |
| SCHEMBL775158 | 0.83 | ABL1 (0.61) | KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL774074 | 0.83 | KCNQ3 (0.52) | KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL3208598 | 0.81 | POLB (0.70) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071513-A1 | Compositions and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2012-03-22 | — | — | US | claimed |
| US-20110178087-A1 | Compositions and Their Use as Anti-Tumor Agents | Compass Pharmaceuticals LLC. (US) | 2011-07-21 | — | — | US | claimed |
| EP-1802606-B1 | ARYLCARBOXAMIDES AND THEIR USE AS ANTI-TUMOR AGENTS | COMPASS PHARMACEUTICALS LLC (US) | 2011-03-16 | — | — | EP | claimed |
| US-20090018145-A1 | Compositions and their use as anti-tumor agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-01-15 | — | — | US | claimed |
| US-20120071513-A1 | Compositions and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110178087-A1 | Compositions and Their Use as Anti-Tumor Agents | Compass Pharmaceuticals LLC. (US) | 2011-07-21 | — | — | US | disclosed |
| EP-1802606-B1 | ARYLCARBOXAMIDES AND THEIR USE AS ANTI-TUMOR AGENTS | COMPASS PHARMACEUTICALS LLC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20090018145-A1 | Compositions and their use as anti-tumor agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071513-A1 | Compositions and Their Use as Anti-Tumor Agents | TP53, VHL, RB1 | KCNQ3 4350/4885KCNQ2 4479/4885KCNE1 4695/4885 |
| US-20110178087-A1 | Compositions and Their Use as Anti-Tumor Agents | TP53, VHL, RB1 | KCNQ3 4350/4885KCNQ2 4479/4885KCNE1 4695/4885 |
| US-20090018145-A1 | Compositions and their use as anti-tumor agents | TP53, VHL, RB1 | KCNQ3 4027/4885KCNQ2 4317/4885KCNE1 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.